AATec Medical Welcomes Professor James Chalmers to Scientific Advisory Board

AATec Medical GmbH, a biotech firm specializing in recombinant alpha-1 antitrypsin (AAT), announced the addition of Professor James Chalmers to its Scientific Advisory Board. Professor Chalmers, an expert in respiratory medicine, will lend his expertise to advance AATec's lead product candidate, ATL-105, aimed at treating non-CF bronchiectasis.

Dr. Rüdiger Jankowsky, co-founder and CEO of AATec, expressed enthusiasm about the appointment. He highlighted the value of Professor Chalmers' extensive experience in respiratory health. The addition aims to fortify AATec's research as they approach a proof-of-concept study in bronchiectasis.

Professor Chalmers, based at the University of Dundee, is a notable figure in respiratory medicine with over 450 peer-reviewed papers. He expressed excitement about contributing to AATec’s project, noting the promising potential of recombinant AAT through inhaled delivery.

With Professor Chalmers on board, AATec solidifies its Scientific Advisory Board, which already includes experts like Prof. Dr. Claus Franz Vogelmeier and Prof. Dr. Ulrike Protzer. This development underscores AATec’s commitment to unlocking AAT’s full therapeutic potential.